© 2011, Crown Copyright.
Included under terms of UK Non-commercial Government License.
Bookshelf ID: NBK109546
< PrevNext >
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
< PrevNext >
Palivizumab for Immunoprophylaxis of Respiratory Syncytial Virus (RSV) Bronchiolitis in High-Risk Infants and Young Children: Systematic Review and Additional Economic Modelling of Subgroup Analyses
Health Technology Assessment, No. 15.5
D Wang, S Bayliss, and C Meads.
Author Information and AffiliationsSouthampton (UK): NIHR Journals Library; 2011 Jan.
Abstract
Background:
Respiratory syncytial virus (RSV) is a seasonal infectious disease, with epidemics occurring annually from October to March in the UK. It is a very common infection in infants and young children and can lead to hospitalisation, particularly in those who are premature or who have chronic lung disease (CLD) or congenital heart disease (CHD). Palivizumab (Synagis®, MedImmune) is a monoclonal antibody designed to provide passive immunity against RSV and thereby prevent or reduce the severity of RSV infection. It is licensed for the prevention of serious lower respiratory tract infection caused by RSV in children at high risk. While it is recognised that a policy of using palivizumab for all children who meet the licensed indication does not meet conventional UK standards of cost-effectiveness, most clinicians feel that its use is justified in some children.
Objectives:
To use systematic review evidence to estimate the cost-effectiveness of immunoprophylaxis of RSV using palivizumab in different subgroups of children with or without CLD or CHD who are at high risk of serious morbidity from RSV infection.
Data sources:
A systematic review of the literature and an economic evalutaion was carried out. The bibliographic databases included the Cochrane Library [Cochrane Central Register of Controlled Trials (CENTRAL), Cochrane Database of Systematic Reviews (CDSR), Database of Abstracts of Reviews of Effects (DARE) and Health Technology Assessment (HTA)] and five other databases, from inception to 2009. Research registries of ongoing trials including Current Controlled Trials metaRegister, Clinical Trials.gov and the National Institute for Health Research Clinical Research Network Portfolio were also searched.
Review methods:
Searches were conducted for prognostic and hospitalisation studies covering 1950–2009 (the original report searches conducted in 2007 covering the period 1950–2007 were rerun in August 2009 to cover the period 2007–9) and the database of all references from the original report was sifted to find any relevant studies that may have been missed. The risk factors identified from the systematic review of included studies were analysed and synthesised using stata. The base-case decision tree model developed in the original HTA journal publication [Health Technol Assess 2008;12(36)] was used to derive the cost-effectiveness of immunoprophylaxis of RSV using palivizumab in different subgroups of pre-term infants and young children who are at high risk of serious morbidity from RSV infection. Cost-effective spectra of prophylaxis with palivizumab compared with no prophylaxis for children without CLD/CHD, children with CLD, children with acyanotic CHD and children with cyanotic CHD were derived.
Results:
Thirteen studies were included in this analysis. Analysis of 16,128 subgroups showed that prophylaxis with palivizumab may be cost-effective [at a willingness-to-pay threshold of £30,000/quality-adjusted life-year (QALY)] for some subgroups. For example, for children without CLD or CHD, the cost-effective subgroups included children under 6 weeks old at the start of the RSV season who had at least two other risk factors that were considered in this report and were born at 24 weeks gestational age (GA) or less, but did not include children who were > 9 months old at the start of the RSV season or had a GA of > 32 weeks. For children with CLD, the cost-effective subgroups included children < 6 months old at the start of the RSV season who were born at 28 weeks GA or less, but did not include children who were > 21 months old at the start of the RSV season. For children with acyanotic CHD, the cost-effective subgroups included children < 6 months old at the start of the RSV season who were born at 24 weeks GA or less, but did not include children who were > 21 months old at the start of the RSV season. For children with cyanotic CHD, the cost-effective subgroups included children < 6 weeks old at the start of the RSV season who were born at 24 weeks GA or less, but did not include children who were > 12 months old at the start of the RSV season.
Limitations:
The poor quality of the studies feeding numerical results into this analysis means that the true cost-effectiveness may vary considerably from that estimated here. There is a risk that the relatively high mathematical precision of the point estimates of cost-effectiveness may be quite inaccurate because of poor-quality inputs.
Conclusions:
Prophylaxis with palivizumab does not represent good value for money based on the current UK incremental cost-effectiveness ratio threshold of £30,000/QALY when used unselectively in children without CLD/CHD or children with CLD or CHD. This subgroup analysis showed that prophylaxis with palivizumab may be cost-effective (at a willingness-to-pay threshold of £30,000/QALY) for some subgroups. In summary, the cost-effective subgroups for children who had no CLD or CHD must contain at least two other risk factors apart from GA and birth age. The cost-effective subgroups for children who had CLD or CHD do not necessarily need to have any other risk factors. Future research should be directed towards conducting much larger, better powered and better reported studies to derive better estimates of the risk factor effect sizes.
Funding:
This report was funded by the HTA programme of the National Institute for Health Research.
Contents
- NIHR Health Technology Assessment programme
- Glossary
- List of abbreviations
- Executive summary
- 1. Aim of the report
- 2. Background
- 3. Definition of the decision problem
- 4. Assessment of clinical effectiveness
- 5. Assessment of cost-effectiveness
- 6. Summary of key results
- 7. Discussion
- 8. Conclusions
- Acknowledgements
- References
- Appendix 1 Literature search strategies
- Appendix 2 Table of excluded studies with rationale
- Appendix 3 Quality assessment of included studies
- Health Technology Assessment programme
Suggested citation:
Wang D, Bayliss S, Meads C. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses. Health Technol Assess 2011;15(5).
Declared competing interests of authors: none
The research reported in this issue of the journal was commissioned by the HTA programme as project number 06/29/02. The contractual start date was in July 2009. The draft report began editorial review in December 2009 and was accepted for publication in September 2010. As the funder, by devising a commissioning brief, the HTA programme specified the research question and study design. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the referees for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.
The views expressed in this publication are those of the authors and not necessarily those of the HTA programme or the Department of Health.
- NLM CatalogRelated NLM Catalog Entries
- Review Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation.[Health Technol Assess. 2008]Review Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation.Wang D, Cummins C, Bayliss S, Sandercock J, Burls A. Health Technol Assess. 2008 Dec; 12(36):iii, ix-x, 1-86.
- Review A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis.[J Manag Care Pharm. 2010]Review A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis.Frogel MP, Stewart DL, Hoopes M, Fernandes AW, Mahadevia PJ. J Manag Care Pharm. 2010 Jan-Feb; 16(1):46-58.
- Review Updated cost-effectiveness analysis of palivizumab (Synagis) for the prophylaxis of respiratory syncytial virus in infant populations in the UK.[J Med Econ. 2020]Review Updated cost-effectiveness analysis of palivizumab (Synagis) for the prophylaxis of respiratory syncytial virus in infant populations in the UK.Narayan O, Bentley A, Mowbray K, Hermansson M, Pivonka D, Kemadjou EN, Belsey J. J Med Econ. 2020 Dec; 23(12):1640-1652. Epub 2020 Oct 27.
- Review Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.[Cochrane Database Syst Rev. 2013]Review Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Bacic Vrca V, Barsic B. Cochrane Database Syst Rev. 2013 Apr 30; (4):CD006602. Epub 2013 Apr 30.
- Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis.[Pharmacoeconomics. 2007]Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis.Nuijten MJ, Wittenberg W, Lebmeier M. Pharmacoeconomics. 2007; 25(1):55-71.
- Palivizumab for Immunoprophylaxis of Respiratory Syncytial Virus (RSV) Bronchiol...Palivizumab for Immunoprophylaxis of Respiratory Syncytial Virus (RSV) Bronchiolitis in High-Risk Infants and Young Children: Systematic Review and Additional Economic Modelling of Subgroup Analyses
- Different temperature thresholds for antipyretic intervention in critically ill ...Different temperature thresholds for antipyretic intervention in critically ill children with fever due to infection: the FEVER feasibility RCT
- Nurse-delivered sleep restriction therapy to improve insomnia disorder in primar...Nurse-delivered sleep restriction therapy to improve insomnia disorder in primary care: the HABIT RCT
- A high-dose preparation of lactobacilli and bifidobacteria in the prevention of ...A high-dose preparation of lactobacilli and bifidobacteria in the prevention of antibiotic-associated and Clostridium difficile diarrhoea in older people admitted to hospital: a multicentre, randomised, double-blind, placebo-controlled, parallel arm trial (PLACIDE)
- Aquatic therapy for children with Duchenne muscular dystrophy: a pilot feasibili...Aquatic therapy for children with Duchenne muscular dystrophy: a pilot feasibility randomised controlled trial and mixed-methods process evaluation
Your browsing activity is empty.
Activity recording is turned off.
See more...